Name: AIRFREE T800 Filterless Air Purifier,Capacity 180 sq. ft.,Each,T800
Brand: AIRFREE
SKU: 1187866277
Price: 99 USD
Availability: InStock

AIRFREE T800 Filterless Air Purifier,Capacity 180 sq. ft.,Each,T800 - 1187866277

By AIRFREE

$99.00

(38 Reviews)

Model

1187866277

Store

Health Products For You
Premium Online Retailer Of Health Products, Medical Supplies & HomeCare Medical Equipments. Healthcare & Healthy Living Store. Affordable Healthcare Essentials.

Manufacturer

AIRFREE

Detail

AIRFREE T800 Filterless Air Purifier has patented Thermodynamic TSS Technology that destroys mold, dust mites, bacteria, viruses, pollens, dander, tobacco and other organic allergens. Airfree also reduces indoor harmful ozone levels. It is perfect for mold-contaminated areas as well as asthma and allergy sufferers. The exclusive technology of Airfree is completely silent and does not require any filters or maintenance. Just plug it in and let it do the job. Awarded design of Airfree perfectly fits your home decor. Specially developed for smaller rooms. The T800 offers the same performance and efficiency as other Airfree series. This unique and elegant design will not compromise essential space in any room.Where T-800 Air Purifier can be used?Helps relief respiratory allergies & asthmaChildren and newborn roomsYachts, cruisers, boats, RVsVideo, films, sound & optical equipmentHealthy rooms with pure clean airSchools, kindergartensHospitals, clinics, and laboratoriesOffices, public buildingsLibraries, museums, archivesKitchens and pantries food preservationRestaurantsHotels, motels and retire homes

Category

Respiratory

Background In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) ≥12 years of age who have at least one F508del allele. The aim of this study is to assess long-term safety and efficacy of ELX/TEZ/IVA in these patients. Methods In this phase 3, open-label, single-arm extension study, participants with F508del –minimal function (from a 24-week parent study; n=399) or F508del – F508del (from a 4-week parent study; n=107) genotypes receive ELX/TEZ/IVA at the same dose (ELX 200 mg once daily, TEZ 100 mg once daily and IVA 150 mg every 12 h). The primary end-point is safety and tolerability. A prespecified interim analysis was conducted when the last participant reached the Week 144 visit. Results At the Week 144 in...

>Read More

Background Hypoxic burden (HB) has emerged as a strong predictor of cardiovascular risk in obstructive sleep apnoea (OSA). We aimed to assess the potential of HB to predict the cardiovascular benefit of treating OSA with continuous positive airway pressure (CPAP). Methods This was a post hoc analysis of the ISAACC trial ( ClinicalTrials.gov : NCT01335087) including non-sleepy patients with acute coronary syndrome (ACS) diagnosed with OSA (apnoea–hypopnoea index ≥15 events·h –1 ) by respiratory polygraphy. Patients were randomised to CPAP or usual care and followed for a minimum of 1 year. HB was calculated as the total area under all automatically identified desaturations divided by total sleep time. Patients were categorised as having high or low baseline HB according to the median value (73.1%min·h –1 ). Multivariable Cox regression...

>Read More

Extract Obstructive sleep apnoea (OSA) is the most common form of sleep disordered breathing, affecting nearly one billion middle-aged individuals worldwide [1]. OSA is extensively accepted as a significant risk factor for a variety of cardiovascular diseases, including hypertension, coronary heart disease, stroke and arrhythmias [2]. First-line, gold-standard therapy for moderate-to-severe OSA is continuous positive airway pressure (CPAP), which secures the upper airway during sleep, eliminates apnoeas and hypopnoeas and restores sleep architecture [3]. One of the major unresolved questions in the field of sleep apnoea is whether treatment with CPAP prevents incidents cardiovascular events and mortality. The hypothesis underlying three pivotal randomised controlled trials (RCTs) (SAVE, ISAACC and RICCADSA) was to consider sleep apnoea as an independent cardiovascular risk factor. A r...

>Read More

Extract Since the discovery of the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene in 1989, greater understanding of gene variants and their functional consequences have raised the ambition of treating the underlying cause of cystic fibrosis (CF) and thereby changing the disease trajectory of this life-limiting progressive condition [1]. Recent successful efforts have targeted the dysfunctional protein product formed as a result of gene variants in an effort to improve its function. In a landmark trial, a novel compound, ivacaftor, increased protein function for a subset of individuals with a specific CFTR gene variant as measured by the biomarker sweat chloride [2]. This improvement translated to meaningful clinical benefits in terms of lung function, the frequency of pulmonary exacerbations and nutritional status [2]. Approximately 5% of people with CF were carri...

>Read More

Product Details for 1187866277